ArticleNature2021
Structure, function and pharmacology of human itch GPCRs.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.
0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed
12.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 213 citations in OpenAlex.
- Development of a clinically viable MRGPRX4 inverse agonist for cholestatic itch treatment.Nature chemical biology · 2026Article
- Article
- De novo design of miniproteins targeting GPCRs.Nature · 2026Article
- An Itch Receptor Drives Melanoma.bioRxiv : the preprint server for biology · 2026Article
- Structural determinants of ligand response specificity in the mast cell activating GPCR, MRGPRX2.The Journal of biological chemistry · 2026Article
- Structural insight into ligand binding and activation of the orphan GPCR Mas1.The EMBO journal · 2026Article
- Opioid-Induced Constipation: Mechanistic Insights, Experimental Models, and Future Perspectives.Biomedicines · 2026Review
- In silico discovery of nanobody binders to a G-protein coupled receptor using AlphaFold-Multimer.Nature communications · 2026Article
- Direct protamine activation of human mast cells is MRGPRX2-dependent and is modulated by heparin.The Journal of pharmacology and experimental therapeutics · 2026Article
- MRGPRX2 as a novel therapeutic target in headache.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Review
- Berbamine Attenuates Chronic Kidney Disease-Associated Pruritus by Targeting MRGPRX1/MrgprC11 Signaling.Applied biochemistry and biotechnology · 2026Article
- In silico assessment of neuromuscular blocking agents and fluoroquinolones as ligands of the Mas-related G protein-coupled receptor X2.Pharmacological reports : PR · 2026Article
- Structural analysis reveals that water molecules mediate self-activation of GPR99.Communications biology · 2026Article
- Designing Rigid Protein Fiducials to Visualize GPCR Conformational States.bioRxiv : the preprint server for biology · 2026Article
- Regulation of MRGPRX2-mediated mast cell function by competence-stimulating peptide 1 and pro-adrenomedullin peptide.Frontiers in immunology · 2026Article
- Itching, Ionic Channels, Immune System, Magnesium and Antioxidants.Clinical, cosmetic and investigational dermatology · 2026Review
- Modulation of Mast Cell Activation via MRGPRX2 by Natural Oat Extract.International journal of molecular sciences · 2025Article
- Molecular insights into ligand recognition and signaling of OXGR1.Nature communications · 2025Article
- Molecular insights into ago-allosteric modulation at cysteinyl leukotriene receptor 2.Nature communications · 2025Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
29 authors at 6 institutions in 2 countries.
Can Cao *Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Hye Jin Kang *Department of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Isha SinghDepartment of Pharmaceutical Sciences, University of California San Francisco, School of Medicine, San Francisco, CA, USA.
He ChenMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Chengwei ZhangMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Wenlei YeDepartment of Physiology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0002-4694-1493
Byron W HayesDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.
Jing LiuMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-4740-243X
Ryan H GumpperDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Brian J BenderDepartment of Pharmaceutical Sciences, University of California San Francisco, School of Medicine, San Francisco, CA, USA.
Samuel T SlocumDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Brian E KrummDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-6039-4767
Katherine LansuDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
John D McCorvyDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0001-7555-9413
Wesley K KroezeDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Justin G EnglishDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Jeffrey F DiBertoDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Reid H J OlsenDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Xi-Ping HuangDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Shicheng ZhangDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-5245-443X
Yongfeng LiuDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-8649-7892
Kuglae KimDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Joel KarpiakDepartment of Pharmaceutical Sciences, University of California San Francisco, School of Medicine, San Francisco, CA, USA.
Lily Y JanDepartment of Physiology, University of California, San Francisco, San Francisco, CA, USA.ORCID http://orcid.org/0000-0003-3938-8498
Soman N AbrahamDepartment of Pathology, Duke University Medical Center, Durham, NC, USA.
Jian JinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences and Neuroscience, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-2387-3862
Brian K ShoichetDepartment of Pharmaceutical Sciences, University of California San Francisco, School of Medicine, San Francisco, CA, USA. bshoichet@gmail.com.ORCID http://orcid.org/0000-0002-6098-7367
Jonathan F FayDepartment of Biochemistry and Biophysics, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA. fayj@unc.edu.ORCID http://orcid.org/0000-0003-1822-2384
Bryan L RothDepartment of Pharmacology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA. bryan_roth@med.unc.edu.ORCID http://orcid.org/0000-0002-0561-6520
University of North Carolina at Chapel Hill · USUniversity of California, San Francisco · USIcahn School of Medicine at Mount Sinai · USDuke Medical Center · USHoward Hughes Medical Institute · USNational University of Singapore · SG
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5MIlluminating the Druggable GPCR-omeU24DK116195 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ROTH, BRYAN L., SHOICHET, BRIAN K · 2017 to 2022
$14.3MDevelopment and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5MDuke KURe ProgramK12DK100024 · NIDDK · DUKE UNIVERSITY · PI Cindy Amundsen · 2013 to 2026
$8.4MSTRUCTURE AND FUNCTION OF MRG-FAMILY RECEPTORSR01DA055656 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Bryan L. Roth, Brian K Shoichet · 2022 to 2026
$2.8MLoss of Bladder Control Following Recurrent InfectionsR01DK121969 · NIDDK · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2020 to 2023
$1.6MAberrant remodeling of bladder following infectionR01DK121032 · NIDDK · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2019 to 2022
$1.6MImmunotherapy to combat skin infectionsR56AI139620 · NIAID · DUKE UNIVERSITY · PI ABRAHAM, SOMAN N · 2019 to 2019
$279kHoward Hughes Medical InstituteNCI NIH HHS P30 CA016086NIAID NIH HHS R56 AI139620NIDA NIH HHS R01 DA055656NIDDK NIH HHS K12 DK100024NIDDK NIH HHS R01 DK121032NIDDK NIH HHS R01 DK121969NIDDK NIH HHS U24 DK116195NIGMS NIH HHS R35 GM122481
Abstract
The MRGPRX family of receptors (MRGPRX1-4) is a family of mas-related G-protein-coupled receptors that have evolved relatively recently
Indexed as
Cryoelectron MicroscopyDrug Inverse AgonismGTP-Binding Protein alpha Subunits, Gi-GoGTP-Binding Protein alpha Subunits, Gq-G11HumansModels, MolecularNerve Tissue ProteinsPruritusReceptors, G-Protein-CoupledReceptors, NeuropeptideGTP-Binding Protein alpha Subunits, Gi-GoGTP-Binding Protein alpha Subunits, Gq-G11MRGPRX2 protein, humanMRGPRX4 protein, humanNerve Tissue ProteinsReceptors, G-Protein-CoupledReceptors, Neuropeptide
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.